Towards a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal
Preprint
Abstract
Background: Retrieval of adverse event reports based on coded drug-event co-occurrence enables large-scale pharmacovigilance analyses, but yields candidate reports rather than validated cases, risking misinterpretation if used alone. Aim: To develop and apply a framework for identification and characterization of clinically meaningful case series in pharmacovigilance. Methods: We conducted two case studies. The first developed and refined the framework in an information-rich setting, focusing on drug-induced impulsivity across selected drugs; the second tested its applicability in a more routine, information-poor setting, focusing on drug-induced suicidality. Results: In Case 1, non-relevant reports were frequent for drugs with uncertain evidence and negative controls (≈20-40%) compared to drugs with established causal roles (4%). The emerging framework assessed relevance based on exposure, event, drug-event relationship, and population. For suspected adverse drug reactions, relevant reports were further characterized by reporter suspicion and evidentiary qualifiers supporting or refuting causality; higher suspicion was associated with more supportive qualifiers. Applied to Case 2, the framework ruled out 69% of reports as non-relevant but highlighted substantial non-assessability (17%). Conclusions: In pharmacovigilance, retrieval is not equivalent to case identification. Relevance is question-specific and shaped by how reports are captured, processed, and retrieved. This can be especially critical for emerging or bias-prone safety questions. Transparent and reproducible case definition and adjudication are essential for interpretable analyses. Graphical Code-based retrieval of drug–event co-occurrence yields a heterogeneous set of candidate reports that does not directly correspond to a clinically meaningful case series. The proposed framework separates case identification from retrieval by adjudicating relevance across exposure, event, relationship, and context, ruling out non-relevant or non-assessable reports. Relevant reports are further qualified by reporter suspicion and evidentiary features, enabling more interpretable pharmacovigilance analyses.Keywords
This publication has 27 references indexed in Scilit:
- Strategies and Challenges in Coding Ambiguous Information Using MedDRA®: An Exploration Among Norwegian Pharmacovigilance OfficersDrug Safety, 2025
- Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERSDrug Safety, 2024
- Authors’ Reply to Cappello et al. Comment on: “Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System”Drug Safety, 2023
- Development of a multivariate prediction model to identify individual case safety reports which require clinical reviewPharmacoepidemiology and Drug Safety, 2022
- Towards Automating Adverse Event Review: A Prediction Model for Case Report UtilityDrug Safety, 2020
- When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal DetectionClinical Pharmacology & Therapeutics, 2017
- Dopamine Agonists and Impulse Control Disorders: A Complex AssociationDrug Safety, 2017
- Good Signal Detection Practices: Evidence from IMI PROTECTDrug Safety, 2016
- vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality IssuesDrug Safety, 2013
- Duplicate detection in adverse drug reaction surveillanceData Mining and Knowledge Discovery, 2007